Sai Life Sciences, a leading Contract Research, Development, and Manufacturing Organization (CRDMO), has successfully completed Phase II of its new Production Block (PB-11) at its Bidar manufacturing facility. The new addition has increased the total reactor capacity of the facility to 700 KL, further solidifying Sai Life Sciences’ commitment to meeting the growing global demand for active pharmaceutical ingredients (APIs) and advanced intermediates.
Phase I of PB-11, with a capacity of 110 KL, was inaugurated in December 2024. With Phase II adding another 91 KL, the combined capacity of PB-11 now reaches approximately 200 KL, making it the largest reactor volume block at the Bidar site. This development is a part of Sai Life Sciences’ broader strategy to enhance production capabilities, providing clients with scalable, reliable, and efficient manufacturing solutions.
Krishna Kanumuri, CEO & Managing Director of Sai Life Sciences, emphasized the strategic importance of this expansion, stating, “Our clients are at the heart of everything we do. This expansion at Bidar is more than additional capacity – it’s about ensuring we can scale with our partners’ needs, delivering reliably while managing the increasing complexity of their programs.”
The Bidar facility, Sai Life Sciences’ flagship site, specializes in the production of APIs and intermediates for highly regulated markets, including the US, EU, and Japan. Key highlights of the facility include:
- 12 production blocks with a combined capacity of approximately 700 KL
- Dedicated facilities for high-potency APIs (HPAPIs)
- State-of-the-art quality control laboratories
- Advanced manufacturing capabilities including lyophilization, cryogenic reactions, high-pressure reactions, and commercial-scale chromatography
The site has earned approval from major global regulatory agencies such as the USFDA, PMDA (Japan), and CDSCO (India). As of March 2025, the facility has undergone more than 75 customer audits in the past three years, underlining its dedication to quality, safety, and compliance.
With this expansion, Sai Life Sciences is poised to better support its clients’ needs, accelerate the development of new medicines, and help de-risk global supply chains.